{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T21:49:29Z","timestamp":1781128169969,"version":"3.54.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod. Sci."],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s43032-021-00565-8","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T15:43:00Z","timestamp":1618501380000},"page":"1068-1085","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The Prediction of Recurrence in Low-Risk Endometrial Cancer: Is It Time for a Paradigm Shift in Adjuvant Therapy?"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9455-894X","authenticated-orcid":false,"given":"Mohamed","family":"Laban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9472-9596","authenticated-orcid":false,"given":"Seif Tarek","family":"El-Swaify","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara H.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen A.","family":"Refaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Sabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourhan","family":"Farrag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa Sayed","family":"Hassanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,15]]},"reference":[{"key":"565_CR1","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3389\/fonc.2019.01440","volume":"9","author":"S Zhang","year":"2019","unstructured":"Zhang S, Gong TT, Liu FH, Jiang YT, Sun H, Ma XX, et al. Global, regional, and national burden of endometrial cancer, 1990-2017: results from the Global Burden of Disease Study, 2017. Front Oncol. 2019;9:1440. Published 2019 Dec 19. https:\/\/doi.org\/10.3389\/fonc.2019.01440.","journal-title":"Front Oncol."},{"key":"565_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","volume":"15","author":"JV Bokhman","year":"1983","unstructured":"Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10\u20137.","journal-title":"Gynecol Oncol"},{"key":"565_CR3","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.ygyno.2003.11.048","volume":"92","author":"HM Keys","year":"2004","unstructured":"Keys HM, Roberts JA, Brunetto VL, the Gynecologic Oncology Group, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744\u201351.","journal-title":"Gynecol Oncol"},{"issue":"10023","key":"565_CR4","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(15)00130-0","volume":"387","author":"P Morice","year":"2016","unstructured":"Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet. 2016;387(10023):1094\u2013108. https:\/\/doi.org\/10.1016\/S0140-6736(15)00130-0.","journal-title":"Lancet."},{"issue":"21","key":"565_CR5","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1093\/jnci\/djs374","volume":"104","author":"A Kong","year":"2012","unstructured":"Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J Natl Cancer Inst. 2012;104(21):1625\u201334. https:\/\/doi.org\/10.1093\/jnci\/djs374.","journal-title":"J Natl Cancer Inst."},{"issue":"3","key":"565_CR6","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ygyno.2019.12.028","volume":"156","author":"AL Beavis","year":"2020","unstructured":"Beavis AL, Yen TT, Stone RL, Wethington SL, Carr C, Son J, et al. Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: is there a role for chemotherapy? Gynecol Oncol. 2020;156(3):568\u201374. https:\/\/doi.org\/10.1016\/j.ygyno.2019.12.028.","journal-title":"Gynecol Oncol."},{"key":"565_CR7","unstructured":"Danish Gynecological Cancer Group. Chemotherapy or observation in stage I-II intermediate or high risk endometrial cancer. ClinicalTrials.gov Identifier: NCT01244789 [Internet]. Copenhagen: Danish Gynecological Cancer Group. 2018 [cited 2021 Jan 13]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01244789"},{"issue":"13","key":"565_CR8","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.ejca.2010.06.002","volume":"46","author":"T Hogberg","year":"2010","unstructured":"Hogberg T, Signorelli M, de Oliveira CF, Fossati R, Lissoni AA, Sorbe B, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur J Cancer. 2010;46(13):2422\u201331. https:\/\/doi.org\/10.1016\/j.ejca.2010.06.002.","journal-title":"Eur J Cancer."},{"issue":"5","key":"565_CR9","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1097\/IGC.0000000000000963","volume":"27","author":"D Boothe","year":"2017","unstructured":"Boothe D, Williams N, Odei B, Poppe MM, Werner TL, Suneja G, et al. The addition of adjuvant chemotherapy to radiation in early-stage high-risk endometrial cancer: survival outcomes and patterns of care. Int J Gynecol Cancer. 2017;27(5):912\u201322. https:\/\/doi.org\/10.1097\/IGC.0000000000000963.","journal-title":"Int J Gynecol Cancer."},{"issue":"2","key":"565_CR10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ygyno.2014.06.003","volume":"134","author":"WM Burke","year":"2014","unstructured":"SGO Clinical Practice Endometrial Cancer Working Group, Burke WM, Orr J, et al. Endometrial cancer: a review and current management strategies: part II. Gynecol Oncol. 2014;134(2):393\u2013402. https:\/\/doi.org\/10.1016\/j.ygyno.2014.06.003.","journal-title":"Gynecol Oncol."},{"issue":"6","key":"565_CR11","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1097\/IGC.0000000000000733","volume":"26","author":"Y Xu","year":"2016","unstructured":"Xu Y, Burmeister C, Hanna RK, Munkarah A, Elshaikh MA. Predictors of survival after recurrence in women with early-stage endometrial carcinoma. Int J Gynecol Cancer. 2016;26(6):1137\u201342. https:\/\/doi.org\/10.1097\/IGC.0000000000000733.","journal-title":"Int J Gynecol Cancer."},{"issue":"1","key":"565_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ygyno.2016.10.025","volume":"144","author":"S Bendifallah","year":"2017","unstructured":"Bendifallah S, Ouldamer L, Lavoue V, Canlorbe G, Raimond E, Coutant C, et al. Patterns of recurrence and outcomes in surgically treated women with endometrial cancer according to ESMO-ESGO-ESTRO Consensus Conference risk groups: results from the FRANCOGYN study Group. Gynecol Oncol. 2017;144(1):107\u201312. https:\/\/doi.org\/10.1016\/j.ygyno.2016.10.025.","journal-title":"Gynecol Oncol."},{"issue":"5","key":"565_CR13","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2017.28.e65","volume":"28","author":"N Topfedaisi Ozkan","year":"2017","unstructured":"Topfedaisi Ozkan N, Meydanl\u0131 MM, Sar\u0131 ME, Demirkiran F, Kahramanoglu I, Bese T, et al. Factors associated with survival after relapse in patients with low-risk endometrial cancer treated with surgery alone. J Gynecol Oncol. 2017;28(5):e65. https:\/\/doi.org\/10.3802\/jgo.2017.28.e65.","journal-title":"J Gynecol Oncol."},{"issue":"1","key":"565_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ygyno.2019.04.676","volume":"154","author":"SR Francis","year":"2019","unstructured":"Francis SR, Ager BJ, Do OA, Huang YHJ, Soisson AP, Dodson MK, et al. Recurrent early stage endometrial cancer: patterns of recurrence and results of salvage therapy. Gynecol Oncol. 2019;154(1):38\u201344. https:\/\/doi.org\/10.1016\/j.ygyno.2019.04.676.","journal-title":"Gynecol Oncol."},{"issue":"6","key":"565_CR15","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1136\/ijgc-2020-001241","volume":"30","author":"M Stasenko","year":"2020","unstructured":"Stasenko M, Feit N, Lee SSK, Shepherd C, Soslow RA, Cadoo KA, et al. Clinical patterns and genomic profiling of recurrent \u2018ultra-low risk\u2019 endometrial cancer. Int J Gynecol Cancer. 2020;30(6):717\u201323. https:\/\/doi.org\/10.1136\/ijgc-2020-001241.","journal-title":"Int J Gynecol Cancer."},{"issue":"6","key":"565_CR16","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1136\/ijgc-2019-000910","volume":"30","author":"SR Kim","year":"2020","unstructured":"Kim SR, Pina A, Albert A, McAlpine JN, Wolber R, Gilks B, et al. Mismatch repair deficiency and prognostic significance in patients with low-risk endometrioid endometrial cancers. Int J Gynecol Cancer. 2020;30(6):783\u20138. https:\/\/doi.org\/10.1136\/ijgc-2019-000910.","journal-title":"Int J Gynecol Cancer."},{"issue":"4","key":"565_CR17","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1097\/IGC.0000000000001223","volume":"28","author":"G Sozzi","year":"2018","unstructured":"Sozzi G, Uccella S, Berretta R, Petrillo M, Fanfani F, Monterossi G, et al. Tumor size, an additional risk factor of local recurrence in low-risk endometrial cancer: a large multicentric retrospective study. Int J Gynecol Cancer. 2018;28(4):684\u201391. https:\/\/doi.org\/10.1097\/IGC.0000000000001223.","journal-title":"Int J Gynecol Cancer."},{"issue":"4","key":"565_CR18","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1097\/IGC.0000000000000098","volume":"24","author":"CJ Wang","year":"2014","unstructured":"Wang CJ, Chao A, Yang LY, Hsueh S, Huang YT, Chou HH, et al. Fertility-preserving treatment in young women with endometrial adenocarcinoma: a long-term cohort study. Int J Gynecol Cancer. 2014;24(4):718\u201328. https:\/\/doi.org\/10.1097\/IGC.0000000000000098.","journal-title":"Int J Gynecol Cancer."},{"issue":"1","key":"565_CR19","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/aog.0b013e31827a0643","volume":"121","author":"JY Park","year":"2013","unstructured":"Park JY, Seong SJ, Kim TJ, Kim JW, Kim SM, Bae DS, et al. Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer. Obstet Gynecol. 2013;121(1):136\u201342. https:\/\/doi.org\/10.1097\/aog.0b013e31827a0643.","journal-title":"Obstet Gynecol."},{"issue":"4","key":"565_CR20","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.ejca.2012.09.017","volume":"49","author":"JY Park","year":"2013","unstructured":"Park JY, Kim DY, Kim JH, Kim YM, Kim KR, Kim YT, et al. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). Eur J Cancer. 2013;49(4):868\u201374. https:\/\/doi.org\/10.1016\/j.ejca.2012.09.017.","journal-title":"Eur J Cancer."},{"issue":"3","key":"565_CR21","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00404-019-05418-z","volume":"301","author":"I Ureyen","year":"2020","unstructured":"Ureyen I, Karalok A, Turkmen O, Kimyon G, Akdas YR, Akyol A, et al. Factors predicting recurrence in patients with stage IA endometrioid endometrial cancer: what is the importance of LVSI? Arch Gynecol Obstet. 2020;301(3):737\u201344. https:\/\/doi.org\/10.1007\/s00404-019-05418-z.","journal-title":"Arch Gynecol Obstet."},{"issue":"3","key":"565_CR22","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/ijgc-2018-000069","volume":"29","author":"A Ayhan","year":"2019","unstructured":"Ayhan A, \u015eahin H, Sari ME, Yal\u00e7in I, Haberal A, Meydanli MM. Prognostic significance of lymphovascular space invasion in low-risk endometrial cancer. Int J Gynecol Cancer. 2019;29(3):505\u201312. https:\/\/doi.org\/10.1136\/ijgc-2018-000069.","journal-title":"Int J Gynecol Cancer."},{"issue":"7-8","key":"565_CR23","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1159\/000488112","volume":"41","author":"K G\u00fcng\u00f6rd\u00fck","year":"2018","unstructured":"G\u00fcng\u00f6rd\u00fck K, Firat C\u00fcylan Z, Kahramanoglu I, Oge T, Akbayir O, Dede M, et al. Risk factors for recurrence in low-risk endometrial cancer: a case-control study. Oncol Res Treat. 2018;41(7-8):466\u201370. https:\/\/doi.org\/10.1159\/000488112.","journal-title":"Oncol Res Treat."},{"issue":"2","key":"565_CR24","doi-asserted-by":"publisher","first-page":"204","DOI":"10.4103\/0019-509X.82895","volume":"48","author":"A Yoney","year":"2011","unstructured":"Yoney A, Yildirim C, Bati Y, Unsal M. Low risk stage I endometrial carcinoma: prognostic factors and outcomes. Indian J Cancer. 2011;48(2):204\u201310. https:\/\/doi.org\/10.4103\/0019-509X.82895.","journal-title":"Indian J Cancer."},{"issue":"21","key":"565_CR25","doi-asserted-by":"publisher","first-page":"e6976","DOI":"10.1097\/MD.0000000000006976","volume":"96","author":"KH Han","year":"2017","unstructured":"Han KH, Kim HS, Lee M, Chung HH, Song YS. Prognostic factors for tumor recurrence in endometrioid endometrial cancer stages IA and IB. Medicine (Baltimore). 2017;96(21):e6976. https:\/\/doi.org\/10.1097\/MD.0000000000006976.","journal-title":"Medicine (Baltimore)."},{"issue":"2","key":"565_CR26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00432-016-2276-3","volume":"143","author":"F Kommoss","year":"2017","unstructured":"Kommoss F, Kommoss F, Grevenkamp F, Bunz AK, Taran FA, Fend F, et al. L1CAM: amending the \u201clow-risk\u201d category in endometrial carcinoma. J Cancer Res Clin Oncol. 2017;143(2):255\u201362. https:\/\/doi.org\/10.1007\/s00432-016-2276-3.","journal-title":"J Cancer Res Clin Oncol."},{"issue":"1","key":"565_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12967-018-1515-6","volume":"16","author":"T de Foucher","year":"2018","unstructured":"de Foucher T, Sbeih M, Uzan J, et al. Identification of micro-RNA expression profile related to recurrence in women with ESMO low-risk endometrial cancer. J Transl Med. 2018;16(1):131. Published 2018 May 21. https:\/\/doi.org\/10.1186\/s12967-018-1515-6.","journal-title":"J Transl Med."},{"issue":"1","key":"565_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ygyno.2017.05.002","volume":"146","author":"JY Park","year":"2017","unstructured":"Park JY, Seong SJ, Kim TJ, Kim JW, Bae DS, Nam JH. Significance of body weight change during fertility-sparing progestin therapy in young women with early endometrial cancer. Gynecol Oncol. 2017;146(1):39\u201343. https:\/\/doi.org\/10.1016\/j.ygyno.2017.05.002.","journal-title":"Gynecol Oncol."},{"issue":"3","key":"565_CR29","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ygyno.2019.03.100","volume":"153","author":"MR Moroney","year":"2019","unstructured":"Moroney MR, Davies KD, Wilberger AC, Sheeder J, Post MD, Berning AA, et al. Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers. Gynecol Oncol. 2019;153(3):517\u201320. https:\/\/doi.org\/10.1016\/j.ygyno.2019.03.100.","journal-title":"Gynecol Oncol."},{"issue":"2","key":"565_CR30","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/PGP.0000000000000583","volume":"39","author":"DC Costigan","year":"2020","unstructured":"Costigan DC, Dong F, Nucci MR, Howitt BE. Clinicopathologic and immunohistochemical correlates of CTNNB1 mutated endometrial endometrioid carcinoma. Int J Gynecol Pathol. 2020;39(2):119\u201327. https:\/\/doi.org\/10.1097\/PGP.0000000000000583.","journal-title":"Int J Gynecol Pathol."},{"issue":"15","key":"565_CR31","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1093\/jnci\/djt144","volume":"105","author":"AG Zeimet","year":"2013","unstructured":"Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Abdel Azim S, et al. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation [published correction appears in. J Natl Cancer Inst. 2013;105(15):1142\u201350. https:\/\/doi.org\/10.1093\/jnci\/djt144.","journal-title":"J Natl Cancer Inst."},{"issue":"2","key":"565_CR32","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ygyno.2018.02.012","volume":"149","author":"K Matsuo","year":"2018","unstructured":"Matsuo K, Yabuno A, Hom MS, Shida M, Kakuda M, Adachi S, et al. Significance of abnormal peritoneal cytology on survival of women with stage I-II endometrioid endometrial cancer. Gynecol Oncol. 2018;149(2):301\u20139. https:\/\/doi.org\/10.1016\/j.ygyno.2018.02.012.","journal-title":"Gynecol Oncol."},{"issue":"5","key":"565_CR33","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.3802\/jgo.2019.30.e84","volume":"30","author":"G \u00d8rtoft","year":"2019","unstructured":"\u00d8rtoft G, Lausten-Thomsen L, H\u00f8gdall C, Hansen ES, Dueholm M. Lymph-vascular space invasion (LVSI) as a strong and independent predictor for non-locoregional recurrences in endometrial cancer: a Danish Gynecological Cancer Group Study. J Gynecol Oncol. 2019;30(5):e84. https:\/\/doi.org\/10.3802\/jgo.2019.30.e84.","journal-title":"J Gynecol Oncol."},{"issue":"7","key":"565_CR34","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1097\/IGC.0000000000000490","volume":"25","author":"R dos Reis","year":"2015","unstructured":"dos Reis R, Burzawa JK, Tsunoda AT, Hosaka M, Frumovitz M, Westin SN, et al. Lymphovascular space invasion portends poor prognosis in low-risk endometrial cancer. Int J Gynecol Cancer. 2015;25(7):1292\u20139. https:\/\/doi.org\/10.1097\/IGC.0000000000000490.","journal-title":"Int J Gynecol Cancer."},{"issue":"11","key":"565_CR35","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1038\/bjc.2014.237","volume":"110","author":"S Bendifallah","year":"2014","unstructured":"Bendifallah S, Canlorbe G, Raimond E, Hudry D, Coutant C, Graesslin O, et al. A clue towards improving the European Society of Medical Oncology risk group classification in apparent early stage endometrial cancer? Impact of lymphovascular space invasion. Br J Cancer. 2014;110(11):2640\u20136. https:\/\/doi.org\/10.1038\/bjc.2014.237.","journal-title":"Br J Cancer."},{"issue":"1","key":"565_CR36","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1245\/s10434-015-4583-3","volume":"23","author":"G Canlorbe","year":"2016","unstructured":"Canlorbe G, Bendifallah S, Laas E, Raimond E, Graesslin O, Hudry D, et al. Tumor size, an additional prognostic factor to include in low-risk endometrial cancer: results of a French multicenter study. Ann Surg Oncol. 2016;23(1):171\u20137. https:\/\/doi.org\/10.1245\/s10434-015-4583-3.","journal-title":"Ann Surg Oncol."},{"key":"565_CR37","doi-asserted-by":"publisher","first-page":"10841","DOI":"10.2147\/OTT.S274420","volume":"13","author":"P Jiang","year":"2020","unstructured":"Jiang P, Jia M, Hu J, et al. Prognostic value of Ki67 in patients with stage 1-2 endometrial cancer: validation of the cut-off value of Ki67 as a predictive factor. Onco Targets Ther. 2020;13:10841\u201350. Published 2020 Oct 27. https:\/\/doi.org\/10.2147\/OTT.S274420.","journal-title":"Onco Targets Ther."},{"issue":"1","key":"565_CR38","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2018.29.e9","volume":"29","author":"S Sasada","year":"2018","unstructured":"Sasada S, Yunokawa M, Takehara Y, Ishikawa M, Ikeda S, Kato T, et al. Baseline risk of recurrence in stage I-II endometrial carcinoma. J Gynecol Oncol. 2018;29(1):e9. https:\/\/doi.org\/10.3802\/jgo.2018.29.e9.","journal-title":"J Gynecol Oncol."},{"issue":"4","key":"565_CR39","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1097\/IGC.0000000000000947","volume":"27","author":"EA Bishop","year":"2017","unstructured":"Bishop EA, Java JJ, Moore KN, Walker JL. Pathologic and treatment outcomes among a geriatric population of endometrial cancer patients: an NRG Oncology\/Gynecologic Oncology Group Ancillary Data Analysis of LAP2. Int J Gynecol Cancer. 2017;27(4):730\u20137. https:\/\/doi.org\/10.1097\/IGC.0000000000000947.","journal-title":"Int J Gynecol Cancer."},{"issue":"11","key":"565_CR40","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1038\/bjc.2016.337","volume":"115","author":"L Ouldamer","year":"2016","unstructured":"Ouldamer L, Bendifallah S, Body G, et al. Predicting poor prognosis recurrence in women with endometrial cancer: a nomogram developed by the FRANCOGYN study group. Br J Cancer. 2016;115(11):1296\u2013303. https:\/\/doi.org\/10.1038\/bjc.2016.337.","journal-title":"Br J Cancer."},{"issue":"3","key":"565_CR41","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ygyno.2014.03.567","volume":"133","author":"MM AlHilli","year":"2014","unstructured":"AlHilli MM, Mariani A, Bakkum-Gamez JN, et al. Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer. Gynecol Oncol. 2014;133(3):485\u201393. https:\/\/doi.org\/10.1016\/j.ygyno.2014.03.567.","journal-title":"Gynecol Oncol."},{"issue":"2","key":"565_CR42","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ygyno.2008.10.019","volume":"112","author":"T Fujimoto","year":"2009","unstructured":"Fujimoto T, Nanjyo H, Fukuda J, Nakamura A, Mizunuma H, Yaegashi N, et al. Endometrioid uterine cancer: histopathological risk factors of local and distant recurrence. Gynecol Oncol. 2009;112(2):342\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2008.10.019.","journal-title":"Gynecol Oncol."},{"issue":"13","key":"565_CR43","doi-asserted-by":"publisher","first-page":"4239","DOI":"10.1245\/s10434-014-3864-6","volume":"21","author":"S Bendifallah","year":"2014","unstructured":"Bendifallah S, Canlorbe G, Huguet F, Coutant C, Hudry D, Graesslin O, et al. A risk scoring system to determine recurrence in early-stage type 1 endometrial cancer: a French multicentre study. Ann Surg Oncol. 2014;21(13):4239\u201345. https:\/\/doi.org\/10.1245\/s10434-014-3864-6.","journal-title":"Ann Surg Oncol."},{"issue":"16","key":"565_CR44","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","volume":"22","author":"E Stelloo","year":"2016","unstructured":"Stelloo E, Nout RA, Osse EM, J\u00fcrgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin Cancer Res. 2016;22(16):4215\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2878.","journal-title":"Clin Cancer Res."},{"issue":"7447","key":"565_CR45","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","volume":"497","author":"C Kandoth","year":"2013","unstructured":"Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67\u201373. https:\/\/doi.org\/10.1038\/nature12113.","journal-title":"Nature."},{"issue":"5","key":"565_CR46","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","volume":"29","author":"S Kommoss","year":"2018","unstructured":"Kommoss S, McConechy MK, Kommoss F, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol. 2018;29(5):1180\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdy058.","journal-title":"Ann Oncol."},{"issue":"6","key":"565_CR47","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/modpathol.2015.43","volume":"28","author":"E Stelloo","year":"2015","unstructured":"Stelloo E, Bosse T, Nout RA, MacKay HJ, Church DN, Nijman HW, et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod Pathol. 2015;28(6):836\u201344. https:\/\/doi.org\/10.1038\/modpathol.2015.43.","journal-title":"Mod Pathol."},{"issue":"3","key":"565_CR48","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ygyno.2019.03.098","volume":"153","author":"H Britton","year":"2019","unstructured":"Britton H, Huang L, Lum A, Leung S, Shum K, Kale M, et al. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma. Gynecol Oncol. 2019;153(3):487\u201395. https:\/\/doi.org\/10.1016\/j.ygyno.2019.03.098.","journal-title":"Gynecol Oncol."},{"issue":"29","key":"565_CR49","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1200\/JCO.20.00549","volume":"38","author":"A Le\u00f3n-Castillo","year":"2020","unstructured":"Le\u00f3n-Castillo A, de Boer SM, Powell ME, Mileshkin LR, Mackay HJ, Leary A, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J Clin Oncol. 2020;38(29):3388\u201397. https:\/\/doi.org\/10.1200\/JCO.20.00549.","journal-title":"J Clin Oncol."},{"key":"565_CR50","doi-asserted-by":"publisher","unstructured":"van den Heerik ASVM, Horeweg N, de Boer SM, et al. Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy. International Journal of Gynecologic Cancer. 2020. https:\/\/doi.org\/10.1136\/ijgc-2020-001822.","DOI":"10.1136\/ijgc-2020-001822"},{"issue":"12","key":"565_CR51","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1136\/ijgc-2020-001929","volume":"30","author":"ASVM van den Heerik","year":"2020","unstructured":"van den Heerik ASVM, Horeweg N, Nout RA, Lutgens LCHW, van der Steen-Banasik EM, Westerveld GH, et al. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. Int J Gynecol Cancer. 2020;30(12):2002\u20137. https:\/\/doi.org\/10.1136\/ijgc-2020-001929.","journal-title":"Int J Gynecol Cancer."},{"issue":"1","key":"565_CR52","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ygyno.2018.02.016","volume":"149","author":"J Huvila","year":"2018","unstructured":"Huvila J, Laajala TD, Edqvist PH, Mardinoglu A, Talve L, Pont\u00e9n F, et al. Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma. Gynecol Oncol. 2018;149(1):173\u201380. https:\/\/doi.org\/10.1016\/j.ygyno.2018.02.016.","journal-title":"Gynecol Oncol."},{"issue":"11","key":"565_CR53","doi-asserted-by":"publisher","first-page":"e0188641","DOI":"10.1371\/journal.pone.0188641","volume":"12","author":"T Obata","year":"2017","unstructured":"Obata T, Nakamura M, Mizumoto Y, et al. Dual expression of immunoreactive estrogen receptor \u03b2 and p53 is a potential predictor of regional lymph node metastasis and postoperative recurrence in endometrial endometrioid carcinoma. PLoS One. 2017;12(11):e0188641. Published 2017 Nov 30. https:\/\/doi.org\/10.1371\/journal.pone.0188641.","journal-title":"PLoS One."},{"issue":"7","key":"565_CR54","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/modpathol.2017.15","volume":"30","author":"KC Kurnit","year":"2017","unstructured":"Kurnit KC, Kim GN, Fellman BM, Urbauer DL, Mills GB, Zhang W, et al. CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence. Mod Pathol. 2017;30(7):1032\u201341. https:\/\/doi.org\/10.1038\/modpathol.2017.15.","journal-title":"Mod Pathol."},{"issue":"3","key":"565_CR55","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.ygyno.2017.07.003","volume":"146","author":"CM Cosgrove","year":"2017","unstructured":"Cosgrove CM, Cohn DE, Hampel H, Frankel WL, Jones D, McElroy JP, et al. Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival. Gynecol Oncol. 2017;146(3):588\u201395. https:\/\/doi.org\/10.1016\/j.ygyno.2017.07.003.","journal-title":"Gynecol Oncol."},{"issue":"8","key":"565_CR56","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1097\/IGC.0000000000000801","volume":"26","author":"A Pasanen","year":"2016","unstructured":"Pasanen A, Tuomi T, Isola J, Staff S, B\u00fctzow R, Loukovaara M. L1 cell adhesion molecule as a predictor of disease-specific survival and patterns of relapse in endometrial cancer. Int J Gynecol Cancer. 2016;26(8):1465\u201371. https:\/\/doi.org\/10.1097\/IGC.0000000000000801.","journal-title":"Int J Gynecol Cancer."},{"issue":"11","key":"565_CR57","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1136\/ijgc-2020-001309","volume":"30","author":"E Baxter","year":"2020","unstructured":"Baxter E, Brennan DJ, McAlpine JN, et al. Improving response to progestin treatment of low-grade endometrial cancer. Int J Gynecol Cancer. 2020;30(11):1811\u201323. https:\/\/doi.org\/10.1136\/ijgc-2020-001309.","journal-title":"Int J Gynecol Cancer."}],"container-title":["Reproductive Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-021-00565-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43032-021-00565-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-021-00565-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T16:34:41Z","timestamp":1646843681000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43032-021-00565-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,15]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["565"],"URL":"https:\/\/doi.org\/10.1007\/s43032-021-00565-8","relation":{},"ISSN":["1933-7191","1933-7205"],"issn-type":[{"value":"1933-7191","type":"print"},{"value":"1933-7205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,15]]},"assertion":[{"value":"18 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There is a waiver as the review does not include any study on humans and\/or animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}